2025
臺灣生技進入「專業資本」時代，世代更替、評估模式、投資紀律與人才結構 都需要重新建立！
臺灣資本市場第二檔永續型專業生技基金—倍利生技創業投資(Beiley Biofund，簡稱倍利創投，股票代號：7882)即將9日正式掛牌。
倍利創投的成立，被認為並非單一基金的誕生，而是台灣生技投資邁入「專業化」、「長期化」、「永續化」的分水嶺。
推動倍利創投成立的福邦證券金融集團董事長、現在同時是台灣併購與私募股權協會 (MAPECT)理事長的黃顯華，他接受本刊專訪，從他親歷40多年股票市場跌宕，創投興衰、永續基金到生技投資生態的第一手觀察與心得。
In compliance with EU personal data protection laws, we are committed to protecting and providing you with control over your personal data. By clicking "Accept All", you allow us to place cookies to enhance your experience on this site, help us analyze site performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Agree" you agree to the current settings. For more information, please visit the Privacy Statement.
This website uses cookies
In compliance with EU personal data protection laws, we are committed to protecting your personal data and providing you with control over it. By clicking "Agree", you allow us to place cookies to improve your experience on this site, help us analyze site performance and usage, and allow us to deliver relevant marketing content.
By clicking "Only necessary" you allow us to place only necessary cookies. The website cannot function without these cookies and you cannot switch them off on your system. These cookies are typically set only in response to an action you perform (i.e. a service request), such as setting privacy preferences, logging in, or filling in a form. You can set your browser to block or prompt you for these cookies, but this may prevent some site features from working.
